Cantex Pharmaceuticals announced that azeliragon, a well-tolerated once-a-day pill that inhibits “RAGE” (the receptor for advanced glycation end products), will be featured in four abstracts at this year’s 2024 ASCO Annual Meeting to be held in Chicago....
Cantex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex’ azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic cancer. ...
Cantex Pharmaceuticals announced that Stephen Marcus, M.D., Chief Executive Officer, is participating in the BIO CEO & Investor Conference and is conducting one-on-one meetings with registered investors, showcasing the Company's business and clinical development strategy, recent corporate achievements, and anticipated milestones....
Cantex Pharmaceuticals and Michigan Medicine announced today the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial to evaluate the safety and efficacy of Cantex’s azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19....
Cantex Pharmaceuticals and Allegheny Health Network (AHN), today announced the initiation of a Phase 1/2 study to assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer....
Cantex Pharmaceuticals and Lenox Hill Hospital’s Department of Neurological Surgery announced the initiation of a Phase 2 study to assess the safety and effectiveness of azeliragon in combination with radiation therapy as a treatment for newly diagnosed unmethylated glioblastoma....
Cantex Pharmaceuticals announced today the initiation of a Phase 2 clinical trial to assess the safety and effectiveness of Cantex’s azeliragon combined with stereotactic radiosurgery in patients with brain metastases. ...
Cantex Pharmaceuticals announced the FDA issued a “Study May Proceed” letter for the Phase 2 clinical trial to assess the safety and therapeutic effect of azeliragon in patients with newly diagnosed unmethylated glioblastoma treated with standard of care radiation therapy....
Cantex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma....
Cantex Pharmaceuticals, Inc. today announced that it has secured a global license from Harvard University's Office of Technology Development (OTD) to further develop Cantex's drug azeliragon into a treatment for inflammatory lung diseases including COVID-19....